Selective depletion of tumor-infiltrating regulatory T cells with BAY 3375968, a novel Fc-optimized anti-CCR8 antibody.

Autor: Roider HG; Bayer AG, Pharmaceuticals, Berlin, Germany., Hoff S; Bayer AG, Pharmaceuticals, Berlin, Germany., Tseng SY; Bayer AG, Pharmaceuticals, San Francisco, USA., Berndt S; Bayer AG, Pharmaceuticals, Berlin, Germany., Trautwein M; Bayer AG, Pharmaceuticals, Wuppertal, Germany., Filarsky K; Bayer AG, Pharmaceuticals, Wuppertal, Germany.; Current address: Roche Diagnostics GmbH, Penzberg, Germany., Gritzan U; Bayer AG, Pharmaceuticals, Wuppertal, Germany.; Current address: Memorial Sloan Kettering Cancer Center, New York, USA., Camps J; Bayer AG, Pharmaceuticals, Berlin, Germany., Nadler WM; Bayer AG, Pharmaceuticals, Wuppertal, Germany., Grudzinska-Goebel J; Bayer AG, Pharmaceuticals, Berlin, Germany., Ellinger P; Bayer AG, Pharmaceuticals, Wuppertal, Germany., Pesch T; Bayer AG, Pharmaceuticals, Wuppertal, Germany., Soon CF; Bayer AG, Pharmaceuticals, Wuppertal, Germany., Geyer M; Bayer AG, Pharmaceuticals, Berlin, Germany., Gluske K; Bayer AG, Pharmaceuticals, Berlin, Germany., Stelte-Ludwig B; Bayer AG, Pharmaceuticals, Wuppertal, Germany.; Current address: Vincerx Pharma, Monheim am Rhein, Germany., Gorjánácz M; Bayer AG, Pharmaceuticals, Berlin, Germany. matyas.gorjanacz@bayer.com.

Publikováno v: Clinical and experimental medicine [Clin Exp Med] 2024 Jun 10; Vol. 24 (1), pp. 122. Date of Electronic Publication: 2024 Jun 10.

Targeting the aryl hydrocarbon receptor (AhR) with BAY 2416964: a selective small molecule inhibitor for cancer immunotherapy.

Autor: Kober C; Bayer AG, Pharmaceutical Division, Berlin, Germany.; DKFZ-Bayer Joint Immunotherapy Laboratory (D220), DKFZ-Bayer Joint Immunotherapy Laboratory, Heidelberg, Germany., Roewe J; German Cancer Consortium (DKTK), Clinical Cooperation Unit (CCU), Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center, Heidelberg, Germany.; Department of Neurology, Medical Faculty Mannheim, MCTN, Heidelberg University, Heidelberg, Germany., Schmees N; Bayer AG, Pharmaceutical Division, Berlin, Germany., Roese L; Bayer AG, Pharmaceutical Division, Berlin, Germany., Roehn U; Bayer AG, Pharmaceutical Division, Berlin, Germany., Bader B; Bayer AG, Pharmaceutical Division, Berlin, Germany., Stoeckigt D; Bayer AG, Pharmaceutical Division, Berlin, Germany., Prinz F; Bayer AG, Pharmaceutical Division, Berlin, Germany., Gorjánácz M; Bayer AG, Pharmaceutical Division, Berlin, Germany., Roider HG; Bayer AG, Pharmaceutical Division, Berlin, Germany., Olesch C; Bayer AG, Pharmaceutical Division, Berlin, Germany.; DKFZ-Bayer Joint Immunotherapy Laboratory (D220), DKFZ-Bayer Joint Immunotherapy Laboratory, Heidelberg, Germany., Leder G; Bayer AG, Pharmaceutical Division, Berlin, Germany., Irlbacher H; Bayer AG, Pharmaceutical Division, Berlin, Germany., Lesche R; Bayer AG, Pharmaceutical Division, Berlin, Germany., Lefranc J; Bayer AG, Pharmaceutical Division, Berlin, Germany., Oezcan-Wahlbrink M; Bayer AG, Pharmaceutical Division, Berlin, Germany.; DKFZ-Bayer Joint Immunotherapy Laboratory (D220), DKFZ-Bayer Joint Immunotherapy Laboratory, Heidelberg, Germany., Batra AS; German Cancer Consortium (DKTK), Clinical Cooperation Unit (CCU), Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center, Heidelberg, Germany.; Department of Neurology, Medical Faculty Mannheim, MCTN, Heidelberg University, Heidelberg, Germany., Elmadany N; German Cancer Consortium (DKTK), Clinical Cooperation Unit (CCU), Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center, Heidelberg, Germany.; Department of Neurology, Medical Faculty Mannheim, MCTN, Heidelberg University, Heidelberg, Germany., Carretero R; Bayer AG, Pharmaceutical Division, Berlin, Germany.; DKFZ-Bayer Joint Immunotherapy Laboratory (D220), DKFZ-Bayer Joint Immunotherapy Laboratory, Heidelberg, Germany., Sahm K; German Cancer Consortium (DKTK), Clinical Cooperation Unit (CCU), Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center, Heidelberg, Germany.; Department of Neurology, Medical Faculty Mannheim, MCTN, Heidelberg University, Heidelberg, Germany., Oezen I; German Cancer Consortium (DKTK), Clinical Cooperation Unit (CCU), Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center, Heidelberg, Germany., Cichon F; German Cancer Consortium (DKTK), Clinical Cooperation Unit (CCU), Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center, Heidelberg, Germany., Baumann D; DKFZ-Bayer Joint Immunotherapy Laboratory (D220), DKFZ-Bayer Joint Immunotherapy Laboratory, Heidelberg, Germany., Sadik A; Brain Cancer Metabolism (B350), German Cancer Research Center (DKFZ), Heidelberg, Germany., Opitz CA; Brain Cancer Metabolism (B350), German Cancer Research Center (DKFZ), Heidelberg, Germany., Weinmann H; Bayer AG, Pharmaceutical Division, Berlin, Germany., Hartung IV; Bayer AG, Pharmaceutical Division, Berlin, Germany., Kreft B; Bayer AG, Pharmaceutical Division, Berlin, Germany., Offringa R; DKFZ-Bayer Joint Immunotherapy Laboratory (D220), DKFZ-Bayer Joint Immunotherapy Laboratory, Heidelberg, Germany.; Department of Surgery, University Hospital Heidelberg, Heidelberg, Germany., Platten M; German Cancer Consortium (DKTK), Clinical Cooperation Unit (CCU), Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center, Heidelberg, Germany m.platten@dkfz-heidelberg.de.; Department of Neurology, Medical Faculty Mannheim, MCTN, Heidelberg University, Heidelberg, Germany., Gutcher I; Bayer AG, Pharmaceutical Division, Berlin, Germany.

Publikováno v: Journal for immunotherapy of cancer [J Immunother Cancer] 2023 Nov; Vol. 11 (11).

Meta-Analysis of Human Cancer Single-Cell RNA-Seq Datasets Using the IMMUcan Database.

Autor: Camps J; Biomedical Data Science, Research & Early Development Oncology, Bayer AG, Berlin, Germany., Noël F; Université de Paris, Institut de Recherche Saint-Louis, INSERM U976, Paris, France., Liechti R; Vital-IT group, SIB Swiss Institute of Bioinformatics, Lausanne, Switzerland., Massenet-Regad L; Université de Paris, Institut de Recherche Saint-Louis, INSERM U976, Paris, France.; Université Paris-Saclay, Saint Aubin, France., Rigade S; Université de Paris, Institut de Recherche Saint-Louis, INSERM U976, Paris, France., Götz L; Vital-IT group, SIB Swiss Institute of Bioinformatics, Lausanne, Switzerland., Hoffmann C; Institut Curie, INSERM U932 Research Unit, Department of Surgical Oncology, PSL University, Paris, France., Amblard E; Université de Paris, Institut de Recherche Saint-Louis, INSERM U976, Paris, France.; Université de Paris, Centre de Recherches Interdisciplinaires, Paris, France., Saichi M; Université de Paris, Institut de Recherche Saint-Louis, INSERM U976, Paris, France., Ibrahim MM; Biomedical Data Science, Research & Early Development Premedical, Bayer AG, Wuppertal, Germany., Pollard J; Sanofi Research and Development, Cambridge, Massachusetts., Medvedovic J; Université de Paris, Institut de Recherche Saint-Louis, INSERM U976, Paris, France., Roider HG; Oncology Precision Medicine, Research & Early Development Oncology, Bayer AG, Berlin, Germany., Soumelis V; Université de Paris, Institut de Recherche Saint-Louis, INSERM U976, Paris, France.; Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Saint-Louis, Laboratoire d'Immunologie, Paris, France.; Owkin, Paris, France.

Publikováno v: Cancer research [Cancer Res] 2023 Feb 03; Vol. 83 (3), pp. 363-373.

TGF-β1 potentiates Vγ9Vδ2 T cell adoptive immunotherapy of cancer.

Autor: Beatson RE; King's College London, School of Cancer and Pharmaceutical Sciences, Guy's Cancer Centre, Great Maze Pond, London SE1 9RT, UK., Parente-Pereira AC; King's College London, School of Cancer and Pharmaceutical Sciences, Guy's Cancer Centre, Great Maze Pond, London SE1 9RT, UK., Halim L; King's College London, School of Cancer and Pharmaceutical Sciences, Guy's Cancer Centre, Great Maze Pond, London SE1 9RT, UK., Cozzetto D; Translational Bioinformatics, NIHR Biomedical Research Centre, Guy's and St. Thomas's NHS Foundation Trust and King's College London, London SE1 9RT, UK., Hull C; King's College London, School of Cancer and Pharmaceutical Sciences, Guy's Cancer Centre, Great Maze Pond, London SE1 9RT, UK., Whilding LM; King's College London, School of Cancer and Pharmaceutical Sciences, Guy's Cancer Centre, Great Maze Pond, London SE1 9RT, UK., Martinez O; King's College London, School of Cancer and Pharmaceutical Sciences, Guy's Cancer Centre, Great Maze Pond, London SE1 9RT, UK., Taylor CA; King's College London, School of Cancer and Pharmaceutical Sciences, Guy's Cancer Centre, Great Maze Pond, London SE1 9RT, UK., Obajdin J; King's College London, School of Cancer and Pharmaceutical Sciences, Guy's Cancer Centre, Great Maze Pond, London SE1 9RT, UK., Luu Hoang KN; King's College London, School of Cancer and Pharmaceutical Sciences, Guy's Cancer Centre, Great Maze Pond, London SE1 9RT, UK., Draper B; King's College London, School of Cancer and Pharmaceutical Sciences, Guy's Cancer Centre, Great Maze Pond, London SE1 9RT, UK., Iqbal A; King's College London, School of Cancer and Pharmaceutical Sciences, Guy's Cancer Centre, Great Maze Pond, London SE1 9RT, UK.; Cancer Bioinformatics, King's College London, School of Cancer and Pharmaceutical Sciences, Guy's Cancer Centre, Great Maze Pond, London SE1 9RT, UK., Hardiman T; King's College London, School of Cancer and Pharmaceutical Sciences, Guy's Cancer Centre, Great Maze Pond, London SE1 9RT, UK.; Cancer Bioinformatics, King's College London, School of Cancer and Pharmaceutical Sciences, Guy's Cancer Centre, Great Maze Pond, London SE1 9RT, UK., Zabinski T; King's College London, School of Cancer and Pharmaceutical Sciences, Guy's Cancer Centre, Great Maze Pond, London SE1 9RT, UK., Man F; King's College London, School of Biomedical Engineering and Imaging Sciences, St. Thomas' Hospital, London SE1 7EH, UK., de Rosales RTM; King's College London, School of Biomedical Engineering and Imaging Sciences, St. Thomas' Hospital, London SE1 7EH, UK., Xie J; Bayer Healthcare Innovation Center, Mission Bay, 455 Mission Bay Boulevard South, San Francisco, CA 94158, USA., Aswad F; Bayer Healthcare Innovation Center, Mission Bay, 455 Mission Bay Boulevard South, San Francisco, CA 94158, USA., Achkova D; King's College London, School of Cancer and Pharmaceutical Sciences, Guy's Cancer Centre, Great Maze Pond, London SE1 9RT, UK., Joseph CR; King's College London, School of Cancer and Pharmaceutical Sciences, Guy's Cancer Centre, Great Maze Pond, London SE1 9RT, UK., Ciprut S; King's College London, School of Cancer and Pharmaceutical Sciences, Guy's Cancer Centre, Great Maze Pond, London SE1 9RT, UK., Adami A; King's College London, School of Cancer and Pharmaceutical Sciences, Guy's Cancer Centre, Great Maze Pond, London SE1 9RT, UK., Roider HG; Bayer AG, Müllerstrasse 178, 13342 Berlin, Germany., Hess-Stumpp H; Bayer AG, Müllerstrasse 178, 13342 Berlin, Germany., Győrffy B; Department of Bioinformatics, Semmelweis University, Budapest H1085, Hungary.; Cancer Biomarker Research Group, Research Center for Natural Science, Budapest H1117, Hungary., Quist J; King's College London, School of Cancer and Pharmaceutical Sciences, Guy's Cancer Centre, Great Maze Pond, London SE1 9RT, UK.; Cancer Bioinformatics, King's College London, School of Cancer and Pharmaceutical Sciences, Guy's Cancer Centre, Great Maze Pond, London SE1 9RT, UK., Grigoriadis A; King's College London, School of Cancer and Pharmaceutical Sciences, Guy's Cancer Centre, Great Maze Pond, London SE1 9RT, UK.; Cancer Bioinformatics, King's College London, School of Cancer and Pharmaceutical Sciences, Guy's Cancer Centre, Great Maze Pond, London SE1 9RT, UK., Sommer A; Bayer AG, Müllerstrasse 178, 13342 Berlin, Germany., Tutt ANJ; King's College London, Breast Cancer Now Unit, School of Cancer and Pharmaceutical Sciences, Guy's Cancer Centre, Great Maze Pond, London SE1 9RT, UK., Davies DM; King's College London, School of Cancer and Pharmaceutical Sciences, Guy's Cancer Centre, Great Maze Pond, London SE1 9RT, UK., Maher J; King's College London, School of Cancer and Pharmaceutical Sciences, Guy's Cancer Centre, Great Maze Pond, London SE1 9RT, UK.; Department of Immunology, Eastbourne Hospital, Kings Drive, Eastbourne, East Sussex BN21 2UD, UK.; Department of Clinical Immunology and Allergy, King's College Hospital NHS Foundation Trust, Denmark Hill, London SE5 9RS, UK.; Leucid Bio, Guy's Hospital, Great Maze Pond, London SE1 9RT, UK.

Publikováno v: Cell reports. Medicine [Cell Rep Med] 2021 Dec 21; Vol. 2 (12), pp. 100473. Date of Electronic Publication: 2021 Dec 21 (Print Publication: 2021).

Hepatocyte Growth Factor Receptor overexpression predicts reduced survival but its targeting is not effective in unselected HNSCC patients.

Autor: Khan M; Charité, Berlin, Augustenburger Platz 1, Berlin, Germany., Khaznadar SS; Bayer AG, Research & Development, Pharmaceuticals, Berlin, Germany., Routila J; Centre for Biotechnology, University of Turku and Åbo Akademi University, Turku, Finland.; Department for Otorhinolaryngology - Head and Neck Surgery, Turku University Hospital, Turku, Finland., Ventelä S; Centre for Biotechnology, University of Turku and Åbo Akademi University, Turku, Finland.; Department for Otorhinolaryngology - Head and Neck Surgery, Turku University Hospital, Turku, Finland., Schmid E; Bayer AG, Research & Development, Pharmaceuticals, Berlin, Germany., Gebhart B; Charité, Berlin, Augustenburger Platz 1, Berlin, Germany., Becker ET; Charité, Berlin, Augustenburger Platz 1, Berlin, Germany., Roider HG; Bayer AG, Research & Development, Pharmaceuticals, Berlin, Germany., Perala M; Auria Biobank, Kiinamyllynkatu 8, Turku, Finland., Schmitz AA; Bayer AG, Research & Development, Pharmaceuticals, Berlin, Germany., Krahn T; Bayer AG, Research & Development, Pharmaceuticals, Berlin, Germany., von Ahsen O; Bayer AG, Research & Development, Pharmaceuticals, Berlin, Germany.

Publikováno v: Head & neck [Head Neck] 2020 Apr; Vol. 42 (4), pp. 625-635. Date of Electronic Publication: 2020 Jan 10.